| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/15/2002 | WO2002063308A2 Prediction of wound healing by urinary nitrate assay |
| 08/15/2002 | WO2002063018A2 Method for the production of plant seed with modified fibre content and modified seed coat |
| 08/15/2002 | WO2002063017A2 Integrin-binding chimeras |
| 08/15/2002 | WO2002063015A1 Aspartyl protease |
| 08/15/2002 | WO2002063010A2 Method of producing recombinant antibodies against tumors |
| 08/15/2002 | WO2002063008A2 Intracellular signaling molecules |
| 08/15/2002 | WO2002063007A2 TIMM8b-RELATED PROTEIN |
| 08/15/2002 | WO2002063006A2 Receptors and membrane-associated proteins |
| 08/15/2002 | WO2002063005A2 Lipid-associated molecules |
| 08/15/2002 | WO2002063004A2 G-protein coupled receptors |
| 08/15/2002 | WO2002063003A2 Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof |
| 08/15/2002 | WO2002063002A2 Novel human transporter protein and polynucleotides encoding the same |
| 08/15/2002 | WO2002063000A2 Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same |
| 08/15/2002 | WO2002062999A2 Proteins and nucleic acids encoding same |
| 08/15/2002 | WO2002062997A1 Novel protein and use thereof |
| 08/15/2002 | WO2002062994A1 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals |
| 08/15/2002 | WO2002062989A2 Methods of light activated release 0f ligands from endosomes |
| 08/15/2002 | WO2002062984A1 The yeast with immunoregulation activity to the k cell as well as the production method and the use thereof |
| 08/15/2002 | WO2002062979A2 Enzyme |
| 08/15/2002 | WO2002062978A1 Method and composition for in situ metabolizing of glutathione and nad |
| 08/15/2002 | WO2002062972A2 Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| 08/15/2002 | WO2002062958A2 Prc17: an amplified cancer gene |
| 08/15/2002 | WO2002062955A2 Dendritic enriched secreted lymphocyte activation molecule |
| 08/15/2002 | WO2002062954A2 Antisense modulation of casein kinase 2-beta expression |
| 08/15/2002 | WO2002062952A2 Non-cytotoxic pap mutants |
| 08/15/2002 | WO2002062951A2 Antisense modulation of casein kinase 2-alpha prime expression |
| 08/15/2002 | WO2002062945A2 Compositions and methods relating to lung specific genes and proteins |
| 08/15/2002 | WO2002062944A2 Novel physiologically active peptide and use thereof |
| 08/15/2002 | WO2002062849A2 Isolated human ras-like proteins, nucleic acid molecules encoding them, and uses thereof |
| 08/15/2002 | WO2002062847A2 Superficial zone protein and methods of making and using same |
| 08/15/2002 | WO2002062845A2 Adhesion molecules |
| 08/15/2002 | WO2002062844A2 Long lasting growth hormone releasing factor derivatives |
| 08/15/2002 | WO2002062843A2 Modified erythropoietin (epo) with reduced immunogenicity |
| 08/15/2002 | WO2002062842A1 Modified keratinocyte growth factor (kgf) with reduced immunogenicity |
| 08/15/2002 | WO2002062841A2 Secreted proteins |
| 08/15/2002 | WO2002062840A1 INTERFERON-α INDUCED GENE |
| 08/15/2002 | WO2002062838A1 Binding domain of siah (seven in absentia homolog) protein |
| 08/15/2002 | WO2002062836A2 Detection of antibacterial activity in excretory secretory product of adult trichuris suis |
| 08/15/2002 | WO2002062835A1 Nucleic acids and polypeptides for controlling food intake and/or body weight |
| 08/15/2002 | WO2002062833A2 Modified leptin with reduced immunogenicity |
| 08/15/2002 | WO2002062832A2 Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity |
| 08/15/2002 | WO2002062831A1 Novel peptides, derivatives thereof, process for producing the same, novel strains producing the same and antiviral agents containing the same as the active ingedient |
| 08/15/2002 | WO2002062830A1 Tripeptide derivatives for the treatment of neurodegenerative diseases |
| 08/15/2002 | WO2002062829A1 Peptide derivatives |
| 08/15/2002 | WO2002062828A2 Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases |
| 08/15/2002 | WO2002062823A2 Peptides for facilitating composite receptor expression and translocation of macromolecules |
| 08/15/2002 | WO2002062819A2 Backbone cyclized radiolabelled somatostatin analogs |
| 08/15/2002 | WO2002062818A2 Antisense modulation of casein kinase 2-alpha expression |
| 08/15/2002 | WO2002062810A2 Linkable sialyl lewis x analogs |
| 08/15/2002 | WO2002062750A1 Cannabinoid receptor ligands |
| 08/15/2002 | WO2002062422A1 Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof |
| 08/15/2002 | WO2002062404A2 Closure of ruptured tissue and bulking of tissue |
| 08/15/2002 | WO2002062377A2 Combined use of factor vii polypeptides and factor viii polypeptides |
| 08/15/2002 | WO2002062376A1 Combined use of factor vii polypeptides and factor ix polypeptides |
| 08/15/2002 | WO2002062375A1 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| 08/15/2002 | WO2002062373A2 Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| 08/15/2002 | WO2002062372A2 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| 08/15/2002 | WO2002062371A1 Dipeptide inhibiting angiogenesis in ophthalmopathology |
| 08/15/2002 | WO2002062370A2 Stabilization of hypoallergenic, hyperdigestible previously reduced proteins |
| 08/15/2002 | WO2002062369A2 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| 08/15/2002 | WO2002062368A2 Method of inducing a ctl response |
| 08/15/2002 | WO2002062351A1 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| 08/15/2002 | WO2002062319A2 Microsphere delivery of mucin peptides |
| 08/15/2002 | WO2002062317A2 Bimodal dry powder formulation for inhalation |
| 08/15/2002 | WO2002062316A1 Invasomes for the treatment of disease states, production and use thereof |
| 08/15/2002 | WO2002062297A2 Methods and compositions for modulating gluconeogenesis using pgc-1 |
| 08/15/2002 | WO2002062289A2 Method for treating respiratory distress syndrome |
| 08/15/2002 | WO2002062212A2 A personal condition management system |
| 08/15/2002 | WO2002062205A2 Methods for diagnosing and treating heart disease |
| 08/15/2002 | WO2002062204A2 Methods for diagnosing and treating heart disease |
| 08/15/2002 | WO2002062203A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/15/2002 | WO2002051871A3 Anti-cd28 antibody |
| 08/15/2002 | WO2002051858A3 Antisense modulation of chk2 expression |
| 08/15/2002 | WO2002050101A8 Retinoblastoma-binding protein |
| 08/15/2002 | WO2002039948A3 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| 08/15/2002 | WO2002038035A3 Methods for inhibiting pain |
| 08/15/2002 | WO2002030955A3 Tetrapeptide stimulating functional activity of hepatocytes and its therapeutical use |
| 08/15/2002 | WO2002026968A9 Antisense iap nucleic acids and uses thereof |
| 08/15/2002 | WO2002026249A3 Methods for inhibition of viral infection |
| 08/15/2002 | WO2002024932A3 Expression vectors containing hybrid ubiquitin promoters |
| 08/15/2002 | WO2002022212A8 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 08/15/2002 | WO2002022160A3 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 08/15/2002 | WO2002020732A3 Regulation of human map kinase phosphatase-like enzyme |
| 08/15/2002 | WO2002020567A3 Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein |
| 08/15/2002 | WO2002019966A3 Cardiac arrhythmia treatment methods |
| 08/15/2002 | WO2002018554A3 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof |
| 08/15/2002 | WO2002018369A3 Peptidomimetic protease inhibitors |
| 08/15/2002 | WO2002017901A3 Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma |
| 08/15/2002 | WO2002016381B1 Composition and method for inhibiting platelet aggregation |
| 08/15/2002 | WO2002013763A3 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 08/15/2002 | WO2002008261A3 Bstp-trans protein and related reagents and methods of use thereof |
| 08/15/2002 | WO2002007707A3 Linkage of agents using microparticles |
| 08/15/2002 | WO2002002760A3 25869, a human carboxylesterase and uses thereof |
| 08/15/2002 | WO2002002050A3 Prevention and treatment of mycoplasma-associated diseases |
| 08/15/2002 | WO2002000263A3 Tripeptide prodrug compounds |
| 08/15/2002 | WO2001098466A3 Regulation of human prostasin-like serine protease |
| 08/15/2002 | WO2001092303A3 Human ion channels |
| 08/15/2002 | WO2001092290A3 Ganesin, an 18-residue cysteine-rich defense peptide from spider and related antinicrobial papdides, their preparation and uses. |
| 08/15/2002 | WO2001087285A3 Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors |
| 08/15/2002 | WO2001087270B1 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates |